Sarepta Therapeutics’ (SRPT) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Thursday, Benzinga reports. They currently have a $166.00 price target on the biotechnology company’s stock.

A number of other analysts have also commented on the stock. Citigroup lifted their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a report on Thursday, February 29th. UBS Group lifted their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a buy rating in a report on Friday, March 1st. Evercore ISI lifted their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an in-line rating in a report on Tuesday, February 20th. Wedbush reaffirmed an outperform rating and set a $224.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Finally, Royal Bank of Canada lifted their target price on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an outperform rating in a report on Thursday, February 29th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $160.60.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $133.66 on Thursday. The company has a current ratio of 4.05, a quick ratio of 3.45 and a debt-to-equity ratio of 1.18. The firm has a 50 day moving average of $125.63 and a 200-day moving average of $110.76. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $159.89. The stock has a market capitalization of $12.63 billion, a P/E ratio of 1,215.09 and a beta of 0.95.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. During the same quarter in the previous year, the company posted ($1.44) EPS. Sarepta Therapeutics’s revenue was up 63.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.23 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now directly owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at $2,815,030. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after buying an additional 243,180 shares in the last quarter. Capital International Investors lifted its position in Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in Sarepta Therapeutics by 7.9% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares in the last quarter. Wellington Management Group LLP lifted its position in Sarepta Therapeutics by 5.6% during the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after buying an additional 217,810 shares in the last quarter. Finally, Norges Bank bought a new stake in Sarepta Therapeutics during the 4th quarter worth about $80,697,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.